Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PARL | Q9H300 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450503 | 0.90 | KMT2A (0.57) | TSHRKMT2AMAPK1HPGDPARL | |
| SCHEMBL499428 | 0.88 | KMT2A (0.46) | TSHRKMT2AMAPK1HPGDPARL | |
| SCHEMBL31225415 | 0.88 | SENP1 (0.48) | LMNAABCC4GAATSHRPTGS1 | |
| SCHEMBL31225579 | 0.87 | FAAH (0.53) | FAAHNAAAKMT2AMAPK1HPGD | |
| SCHEMBL31225723 | 0.86 | MAPK1 (0.42) | LMNAABCC4GAATSHRPTGS1 | |
| SCHEMBL31226064 | 0.86 | HSD17B1 (0.45) | FAAHNAAAKMT2AMAPK1HPGD | |
| SCHEMBL31226087 | 0.85 | WNT3A (0.49) | LMNAHTTNAAA | |
| SCHEMBL22415045 | 0.84 | KMT2A (0.46) | TSHRFAAHNAAAKMT2AMAPK1 | |
| SCHEMBL5852228 | 0.82 | CA2 (0.46) | KMT2AMAPK1HPGDRAB9AMEN1 | |
| SCHEMBL31225593 | 0.82 | MMP12 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | ADAXION THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | ADAXION THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024015872-A2 | AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-8710182-B2 | Rapid glycopeptide optimization via neoglycosylation | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-04-29 | — | — | US | disclosed |
| US-8236926-B2 | Chemoselectively ligating sugar moiety to alkoxylamine-containing vancomycin; for inhibiting growth of resistant Enterococci | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2008076483-A9 | RAPID VANCOMYCIN DERIVATIVE PREPARATION VIA NEOGLYCOSYLATION | WISCONSIN ALUMNI RES FOUND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076483-A2 | RAPID VANCOMYCIN DERIVATIVE PREPARATION VIA NEOGLYCOSYLATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080114157-A1 | RAPID GLYCOPEPTIDE OPTIMIZATION VIA NEOGLYCOSYLATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-05-15 | — | — | US | disclosed |
| US-H1638-H | CYCLIC HEXAPEPTIDE | FURUTA TAKAHISA (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | CD74, MICA, HLA-DRB1 | LMNA 4764/4885ABCC4 4423/4885GAA 1281/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | LMNA 2421/4885ABCC4 3837/4885GAA 525/4885 |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | LMNA 4812/4885ABCC4 3885/4885GAA 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.